Drugs / PENNVAX-G DNA
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01260727 | Feb 2010 → Dec 2013 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PENNVAX-G DNA | “PENNVAX-G DNA (HIV-1 env A, C, and D, and consensus gag plasmids) vaccine; 4 mg administered IM as a total volume of 1 mL” NCT01260727 ↗ |
| Known as | PENNVAX-G DNA Vaccine | “PENNVAX-G DNA Vaccine” NCT01260727 ↗ |
| Modality | Vaccine | “PENNVAX-G DNA vaccine” NCT01260727 ↗ |
| Route | Intramuscular | “4 mg administered IM as a total volume of 1 mL” NCT01260727 ↗ |